DanielGStoverMD

Oncology • Columbus, OH

Breast Cancer, Hematologic Oncology

Associate Professor, Medical Oncology

Join to view full profile

Dr. Stover is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Stover's full profile

Already have an account?

Office
1145 Olentangy River Rd
Columbus, OH 43212
Phone+1 614-293-0066

Fax+1 614-293-7264

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2012 - 2015
Vanderbilt University Medical CenterResidency, Internal Medicine, 2008 - 2012
Vanderbilt University School of MedicineClass of 2008

Certifications & Licensure

OH State Medical License 2017 - 2026
MA State Medical License 2012 - 2019
TN State Medical License 2010 - 2013
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrol...
Harry D Bear, Xiaoyan Deng, Dipankar Bandyopadhyay, Michael Idowu, Taylor M Jenkins
Journal for Immunotherapy of Cancer. 2025-02-27
Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer.
Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar
Breast Cancer Research. 2025-02-03
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2025-02-01

Journal Articles

Tumor Fraction in Cell-Free DNA as a Biomarker in Prostate Cancer
Heather A. Parsons, Atish D. Choudhury, Lauren C. Harshman, Daniel G. Stover, The Journal of Clinical Investigation

Press Mentions

New Hormonal Treatment Orserdu Approved for Metastatic Breast CancerFebruary 13th, 2023
Twitter: Dr Toni Choueiri – FDA Approve Pembrolizumab Top Tweet Q4 2021November 4th, 2021
De-Escalation of Radiation Therapy in Patients with Stage I, Node-Negative, HER2-Positive Breast CancerMarch 25th, 2021
Join now to see all